Fintel reports that on December 15, 2025, UBS maintained coverage of Exponent (NasdaqGS:EXPO) with a Neutral recommendation. Analyst Price Forecast Suggests 14.98% Upside As of December 6, 2025, the ...

The new target represents potential upside from Exponent’s current trading price of $76.11, which sits between analysts’ high target of $90 and low target of $76. The price target increase follows ...

Exponent (EXPO) has been quietly grinding higher, with the stock up roughly 4% over the past month and 5% in the past 3 months, even as its one year return remains negative. See our latest analysis ...

Salt Lake City, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, announced today that it will present a ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

In Hans Christian Andersen's folktale, The Emperor's New Clothes, when a child cries out that the emperor is naked, he isn't revealing a secret. Everyone already knows it. What changes in that instant ...

RXRX stock looks like a deep-value growth bet at just $5 and change. Though the technology is exciting, I’m not rushing into shares just yet. Nvidia made early investors rich, but there is a new class ...

Schlenker provided guidance: "For the third quarter 2025, as compared to 1 year prior, we expect revenues before reimbursements to be up in the middle single digits and EBITDA to be 26.75% to 27.75% ...